Literature DB >> 24824474

A rapid ex vivo tissue model for optimising drug detection and ionisation in MALDI imaging studies.

K Huber1, M Aichler, N Sun, A Buck, Z Li, I E Fernandez, S M Hauck, H Zitzelsberger, O Eickelberg, K P Janssen, U Keller, A Walch.   

Abstract

The aim of this study was to establish an ex vivo model for a faster optimisation of sample preparation procedures, for example matrix choice, in matrix-assisted laser desorption/ionisation (MALDI) drug imaging studies. The ionisation properties of four drugs, afatinib, erlotinib, irinotecan and pirfenidone, were determined in an ex vivo tissue experiment by spotting decreasing dilution series onto liver sections. Hereby, the drug signals were distinctly detectable using different matrix compounds, which allowed the selection of the optimal matrix for each drug. The analysis of afatinib and erlotinib yielded high drug signals with α-cyano-4-hydroxycinnamic acid matrix, whereas 2,3-dihydroxybenzoic acid was identified as optimal matrix for irinotecan and pirfenidone detection. Our method was validated by a MALDI drug imaging approach of in vivo treated mouse tissue resulting in corresponding findings, indicating the spotting method as an appropriate approach to determine the matrix of choice. The present study shows the accordance between the detection of ex vivo spotted drugs and in vivo administered drugs by MALDI-TOF and MALDI-FT-ICR imaging, which has not been demonstrated so far. Our data suggest the ex vivo tissue spotting method as an easy and reliable model to optimise MALDI imaging measurements and to predict drug detection in tissue sections derived from treated mice prior to the recruitment of laboratory animals, which helps to save animals, time and costs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24824474     DOI: 10.1007/s00418-014-1223-0

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  25 in total

1.  Direct tissue analysis using matrix-assisted laser desorption/ionization mass spectrometry: practical aspects of sample preparation.

Authors:  Sarah A Schwartz; Michelle L Reyzer; Richard M Caprioli
Journal:  J Mass Spectrom       Date:  2003-07       Impact factor: 1.982

Review 2.  MALDI imaging mass spectrometry: bridging biology and chemistry in drug development.

Authors:  Stephen Castellino; M Reid Groseclose; David Wagner
Journal:  Bioanalysis       Date:  2011-11       Impact factor: 2.681

Review 3.  Mass spectrometric imaging for biomedical tissue analysis.

Authors:  Kamila Chughtai; Ron M A Heeren
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 4.  Current frontiers in clinical research application of MALDI imaging mass spectrometry.

Authors:  Patrick Neubert; Axel Walch
Journal:  Expert Rev Proteomics       Date:  2013-06       Impact factor: 3.940

Review 5.  MALDI imaging mass spectrometry for direct tissue analysis: technological advancements and recent applications.

Authors:  Benjamin Balluff; Cedrik Schöne; Heinz Höfler; Axel Walch
Journal:  Histochem Cell Biol       Date:  2011-07-30       Impact factor: 4.304

6.  Quantitative MALDI tandem mass spectrometric imaging of cocaine from brain tissue with a deuterated internal standard.

Authors:  David A Pirman; Richard F Reich; András Kiss; Ron M A Heeren; Richard A Yost
Journal:  Anal Chem       Date:  2012-12-24       Impact factor: 6.986

7.  Novel mass spectrometry imaging software assisting labeled normalization and quantitation of drugs and neuropeptides directly in tissue sections.

Authors:  Patrik Källback; Mohammadreza Shariatgorji; Anna Nilsson; Per E Andrén
Journal:  J Proteomics       Date:  2012-07-27       Impact factor: 4.044

8.  Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers.

Authors:  Jie Ling; Kim A Johnson; Zhuang Miao; Ashok Rakhit; Michael P Pantze; Marta Hamilton; Bert L Lum; Chandra Prakash
Journal:  Drug Metab Dispos       Date:  2005-12-28       Impact factor: 3.922

9.  Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.

Authors:  Zoë Weaver; Simone Difilippantonio; Julian Carretero; Philip L Martin; Rajaa El Meskini; Anthony J Iacovelli; Michelle Gumprecht; Alan Kulaga; Theresa Guerin; Jerome Schlomer; Maureen Baran; Serguei Kozlov; Thomas McCann; Salvador Mena; Fatima Al-Shahrour; Danny Alexander; Kwok-Kin Wong; Terry Van Dyke
Journal:  Cancer Res       Date:  2012-09-11       Impact factor: 12.701

Review 10.  Analysis of tissue specimens by matrix-assisted laser desorption/ionization imaging mass spectrometry in biological and clinical research.

Authors:  Jeremy L Norris; Richard M Caprioli
Journal:  Chem Rev       Date:  2013-02-11       Impact factor: 60.622

View more
  6 in total

Review 1.  The Histochemistry and Cell Biology pandect: the year 2014 in review.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2015-03-06       Impact factor: 4.304

2.  High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue.

Authors:  Alice Ly; Achim Buck; Benjamin Balluff; Na Sun; Karin Gorzolka; Annette Feuchtinger; Klaus-Peter Janssen; Peter J K Kuppen; Cornelis J H van de Velde; Gregor Weirich; Franziska Erlmeier; Rupert Langer; Michaela Aubele; Horst Zitzelsberger; Liam McDonnell; Michaela Aichler; Axel Walch
Journal:  Nat Protoc       Date:  2016-07-14       Impact factor: 13.491

3.  Supremacy of modern morphometry in typing renal oncocytoma and malignant look-alikes.

Authors:  Franziska Erlmeier; Annette Feuchtinger; Daniela Borgmann; Martina Rudelius; Michael Autenrieth; Axel Karl Walch; Gregor Weirich
Journal:  Histochem Cell Biol       Date:  2015-05-01       Impact factor: 4.304

4.  Mass Spectrometry Imaging of atherosclerosis-affine Gadofluorine following Magnetic Resonance Imaging.

Authors:  Fabian Lohöfer; Rebecca Buchholz; Almut Glinzer; Katharina Huber; Helena Haas; Georgios Kaissis; Annette Feuchtinger; Michaela Aichler; Peter B Sporns; Carsten Höltke; Miriam Stölting; Franz Schilling; René M Botnar; Melanie A Kimm; Cornelius Faber; Axel K Walch; Alma Zernecke; Uwe Karst; Moritz Wildgruber
Journal:  Sci Rep       Date:  2020-01-09       Impact factor: 4.379

5.  MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.

Authors:  Masanobu Nishidate; Kaname Yamamoto; Chinami Masuda; Hiroaki Aikawa; Mitsuhiro Hayashi; Takehiko Kawanishi; Akinobu Hamada
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

6.  Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.

Authors:  Laura Jacobs; Stefan Habringer; Jolanta Slawska; Katharina Huber; Elke Hauf; Zhoulei Li; Yosef Refaeli; Markus Schwaiger; Martina Rudelius; Axel Walch; Ulrich Keller
Journal:  Oncotarget       Date:  2017-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.